NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Core Insights - NewAmsterdam Pharma is set to report topline data from its Phase 3 BROOKLYN clinical trial on July 29, 2024, focusing on oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C levels [1][2] Company Overview - NewAmsterdam Pharma is a late-stage biopharmaceutical company dedicated to improving patient care in populations with metabolic diseases where existing therapies are inadequate or poorly tolerated [5] - The company is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, either alone or in combination with ezetimibe, as a therapy to lower LDL-C levels for patients at risk of cardiovascular disease [5]